Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers
Reviews in Medical Virology · 2026
DOI: 10.1002/rmv.70201 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, 2026. Verfasst von Jingyi Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, China. Hauptthemen laut MEDLINE: Drug Discovery, Neoplasms, Oncogenic Viruses, Network Pharmacology. Die Arbeit nennt 83 Literaturangaben.
Abstract (Originalsprache)
Human oncoviruses, including high‐risk HPV, EBV, HBV, HCV, MCPyV, KSHV, and HTLV‐1, account for approximately 15%–20% of global human malignancies. Rather than acting through isolated pathways, viral oncoproteins systematically rewire host regulatory networks, rendering conventional single‐target oncology paradigms vulnerable to rapid resistance and clinical failure. Systems pharmacology offers a transformative, network‐centric framework that views virus‐driven cancers as systemic perturbations of host protein‐protein interaction networks. This review synthesises computational methodology, network topology, and drug discovery strategies across major human oncoviruses. We examine how graph centrality algorithms, quantitative network proximity metrics (Z‐score), and complementary exposure synergy modelling (S AB ) uncover hidden network vulnerabilities and guide targeted drug repurposing. Despite distinct genomic structures and tissue tropisms, oncogenic viruses converge on shared host interactome hubs, notably TP53, AKT1, BCL2, MYC, STAT3, and VEGFA, to drive cell cycle dysregulation, apoptotic suppression, and microenvironmental remodelling. We evaluate repositioned synthetic pharmaceuticals (such as kinase inhibitors and host ion channel blockers) and multi‐target bioactive formulations, detailing their mechanisms in targeting viral host dependencies. Finally, we address key translational bottlenecks, including disparities between in silico binding predictions and in vivo pharmacokinetics, extensive plasma protein binding, tumour penetration barriers, and viral latency reservoirs. Overcoming these hurdles will require integrating deep graph learning, single‐cell spatial multi‐omics, and patient‐derived organoid models to accelerate the clinical realization of network‐targeted therapies in viral oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, China.
ORCID-Profile: Shuaiting Sun
Zitieren
APA
Sun, J., Song, C., Hua, Y., Pang, J., & Sun, S. (2026). Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70201
Vancouver
Sun J, Song C, Hua Y, Pang J, Sun S. Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70201
BibTeX
@article{Sun2026,
author = {Sun, Jingyi and Song, Changning and Hua, Yining and Pang, Jiayin and Sun, Shuaiting},
title = {Systems Pharmacology of Human Oncoviruses: Network‐Based Drug Discovery for Virus‐Driven Cancers},
journal = {Reviews in Medical Virology},
year = {2026},
doi = {10.1002/rmv.70201}
}
EUVIMED